Ask about this productRelated genes to: SLC35F2 Blocking Peptide
- Gene:
- SLC35F2 NIH gene
- Name:
- solute carrier family 35 member F2
- Previous symbol:
- -
- Synonyms:
- FLJ13018
- Chromosome:
- 11q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-11-25
- Date modifiied:
- 2015-12-04
Related products to: SLC35F2 Blocking Peptide
Related articles to: SLC35F2 Blocking Peptide
- Inter-individual variability in lipid response to dietary modification highlights the critical need for precision nutrition. Current evidence remains fragmented, relying predominantly on restricted candidate-gene studies rather than comprehensive genomic approaches. To bridge this gap, we applied a biologically informed analytical framework to whole-exome sequencing (WES) data to evaluate the nutrigenetics of lipid response in an underrepresented Georgian cohort. Specifically, we explored whether exome-wide and pathway-aggregated genetic variation may contribute to inter-individual differences in LDL cholesterol (ΔLDL-C) and triglyceride (ΔTAG) response to Mediterranean-style dietary guidance. - Source: PubMed
Publication date: 2026/07/16
Iordanishvili SabaChiradze NazibrolaAgladze DodoKikvidze MarineKhuchua ZazaLagani VincenzoSolomonia Revaz - Long non-coding RNAs (LncRNAs) play pivotal roles in lung adenocarcinoma (LUAD) progression. However, the upstream transcriptional regulation and downstream mechanisms of LncRNA NUTM2A-AS1 in LUAD remain largely unexplored. The expression levels of NUTM2A-AS1, TFAP2A, miR-409-5p and SLC35F2 in LUAD tissues and cell lines were analysed using public databases and qRT-PCR. The biological functions of this axis in LUAD cells were evaluated through CCK-8, Transwell and apoptosis assays. The molecular interactions among TFAP2A, NUTM2A-AS1, miR-409-5p and SLC35F2 were validated via chromatin immunoprecipitation (ChIP), dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. Both NUTM2A-AS1 and TFAP2A were significantly upregulated in LUAD and correlated with poor prognosis. Mechanistically, the transcription factor TFAP2A directly bound to the NUTM2A-AS1 promoter to activate its transcription. Functionally, NUTM2A-AS1 promoted LUAD cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT), while suppressing apoptosis. Furthermore, NUTM2A-AS1 may function as a competing endogenous RNA-like regulator by interacting with miR-409-5p, thereby upregulating the expression of the solute carrier family member SLC35F2. Rescue assays demonstrated that SLC35F2 knockdown attenuated the oncogenic phenotypes induced by TFAP2A or NUTM2A-AS1, while miR-409-5p restoration suppressed SLC35F2 expression and cell-cycle progression. Our study supports a TFAP2A/NUTM2A-AS1/miR-409-5p/SLC35F2 regulatory model that contributes to LUAD progression. These findings suggest that the TFAP2A/NUTM2A-AS1/miR-409-5p/SLC35F2 axis contributes to LUAD progression and may provide potential biomarkers and therapeutic targets. - Source: PubMed
Wang WeiqinLiu YongfengChen TiantianZhang JingHu Feng - Genetic variants affect baseline health and biomarker values, which in turn may impact both the therapy selected for an individual and the magnitude of change induced by the medication. Here, we propose an approach for complex longitudinal repeated measures biobank data, which separates genetic effects for disease from the genetic effects for medication usage and those for treatment response. For 211,845 individuals, we construct a pre-post study design from 1,420,443 repeated blood pressure (BP) measurements and 1,117,900 prescription records for common BP influencing drugs, using electronic health records. We model these jointly alongside 8,430,446 imputed single nucleotide polymorphism (SNP) markers and 17,852 whole-exome sequence loss-of-function (LoF) variants, all within a single novel graphical modeling framework. We identify pharmacogenetic candidate SNPs and LoF variants in genes , and , which are associated with angiotensin receptor blocker therapy and response after controlling for hypertensive disease status across multiple worldwide biobanks. We additionally detect and replicate established clinically relevant variants for statin treatment across multiple biobanks. We find that genetic variation for BP is predominantly shaped prior to the age of 50, but we identify 127 independent loci associated with age-specific BP changes later in life. Finally, once post-treatment measures are conditioned on pre-treatment measures and therapy, we find evidence for four independent loci influencing BP treatment response, including a variant in which has previously been associated with diuretic and beta-blocker response. Our graphical modeling and pre-post study design provides a robust way of detecting time-, treatment- and treatment response-specific genetic associations within large-scale biobank studies. - Source: PubMed
Publication date: 2026/03/20
Borczyk MalgorzataMachnik NickHajto JacekKrätschmer IlseKonowalska PaulaBaszkiewicz BartoszKorostynski MichalRobinson Matthew R - Human choroid plexus papilloma (HIBCPP) cells derived from choroid plexus papilloma in the lateral ventricle are considered suitable model cells for the blood-cerebrospinal fluid barrier (BCSFB). Therefore, in this study, the transporters expressed in HIBCPP cells were identified, and the functions of representative transporters were evaluated. - Source: PubMed
Publication date: 2025/12/10
Kurosawa ToshikiOhtsuki SumioIshikawa HiroshiSchroten HorstSchwerk ChristianKubo YoshiyukiDeguchi Yoshiharu - The Solute Carrier (SLC) superfamily of integral membrane proteins transport a wide array of small molecules across plasma and organelle membranes, and function as important drug transporters and as viral receptors. They populate different conformational states during the solute transport process, including outward-open, intermediate (occluded), and inward-open conformational states. For some SLC proteins this structural "flipping" corresponds to swapping between conformations of their N-terminal and C-terminal symmetry-related sub-structures. Conventional AlphaFold2, AlphaFold3, or Evolutionary Scale Modeling methods typically generate models for only one of these multiple conformational states of SLC proteins. While several AI-based protocols for modeling multiple conformational states of proteins have been described recently, these methods are often impacted by "memorization" of one of the alternative conformational states, and do not always provide both the inward- and outward-open conformations of SLC proteins. Here we assess the impact of memorization in modeling SLC proteins with AlphaFold2/3, and describe a combined ESM - template-based-modeling process, based on a previously described template-based modeling method that relies on the internal pseudo-symmetry of many SLC proteins, to consistently model the alternate conformational states of SLC proteins. We also demonstrate how the resulting multi-state models can be validated by comparison with sequence-based evolutionary co-variance data (ECs) that encode information about contacts present in the various conformational states adopted by the protein. This simple, rapid, and robust approach for modeling conformational landscapes of pseudo-symmetric SLC proteins is demonstrated for several integral membrane protein transporters, including SLC35F2 the receptor of a feline leukemia virus envelope protein required for viral entry into eukaryotic cells. - Source: PubMed
Publication date: 2025/10/17
Swapna G V TDube NamitaRoth Monica JMontelione Gaetano T